With the acquisition of Profile Pharma (UK) in 2013, Zambon makes the first step towards the building of its rare diseases products' portfolio, in particular for cystic fibrosis.
The cystic fibrosis is the most common serious genetic disease. In the world, there are about 100,000 people affected.
Zambon has obtained a well-established expertise both in pharmacological and technological perspectives in the respiratory area, achieving today a structured system of therapeutic solutions for treatment of main pathologies characterized by inflammation of mucosa with hypersecretion of mucus and specific preparations specifically tailored to the hygiene of high respiratory tract.
Zambon is also present in the area of Urinary pathologies. Urinary infections represent a frequent and bothersome disease which each year develops in about 20-30% of female population. The therapy of urinary infections is based on administration of antibiotics or urinary disinfectants taken one shot or with multiple doses.